Venus Remedies Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 16.8%)
- Efficient capital deployment (ROCE 21.7%)
- Attractively valued vs sector (P/E 19.5x vs industry 54.7x)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
VENUSREM · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| FII | 1.59% | 1.48% | 1.06% | 1.18% | 1.11% | 1.34% |
| Public | 56.65% | 56.76% | 57.17% | 57.06% | 57.13% | 56.90% |
Latest News
All newsVenus Pipes approves share buyback of up to ₹100 crore
*Venus Pipes approves share buyback of up to ₹100 crore* to return value to shareholders. The buyback will be executed via open market through exchange-traded routes. Key terms include a floor price **₹100 per share** and a maximum **₹100 crore** outlay. The board also approved the issue of secured redeemable non-convertible debentures. 📊 *STOCKS:* $VENUSREM | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #Buyback
Venus Remedies holds shareholder meeting with voting results
*Venus Remedies holds shareholder meeting with voting results*. The company filed voting results and scrutinizer's report. Earlier submission was rejected for not being machine readable. Updated filing now compliant with NSE norms. 📊 *STOCKS:* $VENUSREM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting
Venus Remedies holds annual general meeting
*Venus Remedies holds annual general meeting*. The company submitted the scrutinizers' report of its Annual General Meeting held on August 20, 2026, to the exchange. Voting results were also disclosed, though no material resolutions or major announcements were highlighted. This is a routine compliance update following the AGM. 📊 *STOCKS:* $VENUSREM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Venus Remedies issues updates on physical shares
*Venus Remedies issues updates on physical shares.* The company filed a disclosure related to physical share certificates, though details remain sparse. Such updates typically pertain to compliance or investor communication. Traders should monitor for further clarifications. 📊 *STOCKS:* VENUSREM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #PhysicalShares
Venus Remedies announces AGM date in newspaper notice
*Venus Remedies announces AGM date in newspaper notice.* This is a routine compliance requirement under corporate regulations. No financial or operational updates were provided. The filing ensures shareholders are informed of the upcoming annual general meeting. 📊 *STOCKS:* VENUSREM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Venus Remedies alerts shareholders to update KYC via social media
*Venus Remedies alerts shareholders to update KYC via social media.* The company issued a notice through a social media post to ensure shareholders complete their **KYC updates**. This move aims to improve compliance and communication with investors. No financial impact is expected from this routine update. 📊 *STOCKS:* VENUSREM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #KYC